Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review
© Zimmermann et al; licensee BioMed Central Ltd. 2014
Published: 18 July 2014
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse reactions that are associated with high mortality. Mainly due to rareness, but also due to unpredictable onset and rapid course, therapeutic effects are often studied in observational settings. Since an evidence-based standardized treatment protocol for SJS/TEN is still lacking, we intended to combine information and evidence from any type of study to provide a comprehensive overview on immunomodulating therapies and their potential effects in comparison to supportive care only.
A systematic literature search regarding publications on therapy of SJS/TEN was performed for the period from 1990 to 2012. Any type of study meeting predefined inclusion criteria was included. Data were extracted from published articles. Study groups were contacted to get further information. Eventually, all studies were assessed for final inclusion. To evaluate therapeutic effects we conducted a meta-analyses based on aggregated as well as on individual patient data (IPD).
Besides dozens of observational studies only one randomized controlled trial have been found. The quality of most studies has been assessed as low. 96 studies including 3451 patients passed our selection process. The majority of them focussed on SJS/TEN-patients treated with supportive care, glucocorticosteroids or intravenous immunoglobulines. Few studies evaluated other immunomodulating therapies like ciclosporin, plasmapheresis, cyclophosphamide and thalidomide. Besides monotherapy with one immunomodulating agent combined treatment modalities were also observed. Only 17 studies (18%) assessed therapy effects and are thus principally eligible for inclusion in our common meta-analysis. For the IPD analysis, 1209 patients (35%) with complete information are available. Both analyses are currently ongoing. The results will be presented.
The comprehensive overview about possible therapies for SJS/TEN revealed no unexpected treatment options. Final results of both analyses are awaited for estimating the efficacy of immunomodulating therapies in comparison to supportive care only related to mortality and for providing hypotheses on most promising treatment.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.